Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

@article{Alberer2017SafetyAI,
  title={Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial},
  author={Martin Alberer and Ulrike S Gnad-Vogt and Henoch Sangjoon Hong and Keyvan Tadjalli Mehr and Linus Backert and Greg Finak and Raphael Gottardo and Mihai Alexandru Bica and Aurelio Garofano and Sven D Koch and Mariola Fotin‐Mleczek and Ingmar Hoerr and Ralf Clemens and Frank von Sonnenburg},
  journal={The Lancet},
  year={2017},
  volume={390},
  pages={1511-1520}
}

Figures and Tables from this paper

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
TLDR
Safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, support further evaluation of this mRNA vaccine candidate.
Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies
TLDR
This clinical study proved that mRNA vaccination was safe and had an acceptable reactogenicity profile, but immune responses depended on the mode of administration, and they did not unequivocally support CV7201 for further development as a prophylactic vaccine with this particular formulation.
Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
TLDR
Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels.
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
TLDR
Evidence is provided that CVnCoV represents a potent and safe vaccine candidate against SARS-CoV-2, and hamsters vaccinated with a suboptimal dose of CVn coV leading to breakthrough viral replication exhibited no evidence of vaccine-enhanced disease.
Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection
TLDR
This phase I dose-escalating trial showed that iHIVARNA administration was safe and well tolerated, induced moderate HIV-specific T-cell responses and transiently increased different viral replication readouts, which support further exploration of iHivARNA in a phase II study.
A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C
TLDR
It is demonstrated that one dose of a commercial rabies vaccine effectively boosts the neutralizing antibody responses induced by ChAd155-RG in vaccinated monkeys, showing the compatibility of the novel vectored vaccine with the current post-exposure prophylaxis in the event of rabies virus exposure.
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
TLDR
2 CVnCoV doses were safe, with acceptable reactogenicity and 12 μg dosages elicited levels of immune responses that overlapped those observed in convalescent sera from known COVID-19 patients, an interim analysis of a dosage escalation phase 1 study in healthy 18–60-year-old volunteers.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
TLDR
DNA vaccination by Biojector® was well-tolerated and compared to needle injection, primed for greater IFN-γ ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting.
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
TLDR
It is demonstrated here that such treatment is feasible and safe (phase 1 criteria) and an increase in antitumor humoral immune response was seen in some patients, however, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumors immunotherapy was not shown in this study and must be evaluated in subsequent trials.
An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs
TLDR
This study demonstrates the feasibility of a non-replicating mRNA rabies vaccine in small and large animals and highlights the promises of mRNA vaccines for the prevention of infectious diseases.
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
TLDR
The self-adjuvanted RNActive® vaccine CV9103 was well tolerated and immunogenic, and the technology is a versatile, fast and cost-effective platform allowing for creation of vaccines.
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
TLDR
This trial will assess the safety and tolerability of CV9202 vaccination combined with local radiation designed to enhance immune responses and will include patients with stage IV NSCLC and a response or stable disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor.
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
TLDR
It is shown that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress.
...
...